临床精神医学杂志
臨床精神醫學雜誌
림상정신의학잡지
JOURNAL OF CLINICAL PSYCHOLOGICAL MEDICINE
2015年
3期
176-178
,共3页
郭力%蔡敏%刘高华%乔昱婷%孙润珠%陈云春%谭庆荣
郭力%蔡敏%劉高華%喬昱婷%孫潤珠%陳雲春%譚慶榮
곽력%채민%류고화%교욱정%손윤주%진운춘%담경영
重复经颅磁刺激%广泛性焦虑障碍%度洛西汀
重複經顱磁刺激%廣汎性焦慮障礙%度洛西汀
중복경로자자격%엄범성초필장애%도락서정
repetitive transcranial magnetic stimulation%general anxiety disorder%duloxetine
目的:比较度洛西汀单用或联合重复经颅磁刺激( rTMS)治疗广泛性焦虑障碍( GAD)的临床疗效和安全性。方法:113例GAD患者随机分为研究组( rTMS联合度洛西汀治疗)56例和对照组(单用度洛西汀治疗)57例,疗程4周。采用汉密尔顿焦虑量表( HAMA)、临床疗效总评量表( CGI)、治疗中出现的症状量表( TESS)分别在治疗前后评估疗效和不良反应。结果:研究组显效率76.7%,对照组显效率71.9%(F=1.441,P>0.05)。两组HAMA评分时间主效应存在统计学意义(F=163.12, P<0.05),组间主效应(F=1.44)及交互效应(F=1.62)均无统计学意义(P>0.05)。两组CGI评分组间主效应(F =49.29,P <0.05)、时间主效应(F =1043.00,P <0.001)以及交互效应(F =49.29, P<0.05)均有统计学意义。两组TESS评分差异有统计学意义(t=4.983,P<0.05)。结论:度洛西汀单用或联合rTMS治疗GAD疗效相当,但后者起效更快,不良反应更小。
目的:比較度洛西汀單用或聯閤重複經顱磁刺激( rTMS)治療廣汎性焦慮障礙( GAD)的臨床療效和安全性。方法:113例GAD患者隨機分為研究組( rTMS聯閤度洛西汀治療)56例和對照組(單用度洛西汀治療)57例,療程4週。採用漢密爾頓焦慮量錶( HAMA)、臨床療效總評量錶( CGI)、治療中齣現的癥狀量錶( TESS)分彆在治療前後評估療效和不良反應。結果:研究組顯效率76.7%,對照組顯效率71.9%(F=1.441,P>0.05)。兩組HAMA評分時間主效應存在統計學意義(F=163.12, P<0.05),組間主效應(F=1.44)及交互效應(F=1.62)均無統計學意義(P>0.05)。兩組CGI評分組間主效應(F =49.29,P <0.05)、時間主效應(F =1043.00,P <0.001)以及交互效應(F =49.29, P<0.05)均有統計學意義。兩組TESS評分差異有統計學意義(t=4.983,P<0.05)。結論:度洛西汀單用或聯閤rTMS治療GAD療效相噹,但後者起效更快,不良反應更小。
목적:비교도락서정단용혹연합중복경로자자격( rTMS)치료엄범성초필장애( GAD)적림상료효화안전성。방법:113례GAD환자수궤분위연구조( rTMS연합도락서정치료)56례화대조조(단용도락서정치료)57례,료정4주。채용한밀이돈초필량표( HAMA)、림상료효총평량표( CGI)、치료중출현적증상량표( TESS)분별재치료전후평고료효화불량반응。결과:연구조현효솔76.7%,대조조현효솔71.9%(F=1.441,P>0.05)。량조HAMA평분시간주효응존재통계학의의(F=163.12, P<0.05),조간주효응(F=1.44)급교호효응(F=1.62)균무통계학의의(P>0.05)。량조CGI평분조간주효응(F =49.29,P <0.05)、시간주효응(F =1043.00,P <0.001)이급교호효응(F =49.29, P<0.05)균유통계학의의。량조TESS평분차이유통계학의의(t=4.983,P<0.05)。결론:도락서정단용혹연합rTMS치료GAD료효상당,단후자기효경쾌,불량반응경소。
Objective:To observe the clinical efficacy and safety of repetitive transcranial magnetic stimu-lation( rTMS)combined with duloxetine in the treatment of generalized anxiety disorder( GAD)patients. Method:One hundred and thirteen patients diagnosed as GAD were randomly divided into experimental group ( rTMS plus duloxetine,57 patients)and control group( only duloxetine treatment,56 patients). At the begin-ning of the experiment and at the end of first,second,and fourth week of the trail,the symptom severity,clinical effect and side effects were evaluated by Hamilton anxiety scale( HAMA),the clinical global impression scale (CGI)and the treatment emergent symptom scale(TESS)respectively. Resuits:The marked effective rate (76. 7%) of experimental group was not significantly different from that ( 71. 9%) of control group (F=1. 441,P>0. 05). On HAMA,time main effect(F=163. 12,P<0. 05)was statistically significant,while group main effect( F = 1. 44 ) and interaction effect( F = 1. 62 ) were not statistically significant( all P>0. 05). There were significant group main effect(F=49. 29,P<0. 05),time main effect(F=1043. 00, P<0. 001)and interaction effect(F=49. 29,P<0. 05)on CGI. The two groups showed significant differences on TESS(t=4. 983,P<0. 05). Conciusion:Both two-treatment paradigms have similar clinical outcome. But patients from rTMS plus duloxetine group showed more quickly clinical remission,rare side effect and a bet-ter treatment adherence.